Table of Content


List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Overview
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Companies Involved in Therapeutics Development
Alsonex Pty Ltd
ChemoCentryx Inc
Dompe Farmaceutici SpA
Inte Pharma SA
MorphoSys AG
Prommune Inc
Teva Pharmaceutical Industries Ltd
Visterra Inc
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Drug Profiles
ALS-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avacopan - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
avdoralimab - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
DF-2593A - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Drug to Antagonize C5aR for Periodontitis - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EP-67 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Monoclol Antibody to Antagonize C5AR1 for Anti Neutrophil Cytoplasmic Antibody Associated Vasculitis and Transplant Rejection - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
MOR-210 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PMX-205 - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptides to Antagonize CD88 for Musculoskeletal, Gastrointestil, Autoimmune and Central Nervous System Disorders - Drug Profile
Product Description
Mechanism Of Action
R&D Progress
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Dormant Products
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Discontinued Products
C5a Aphylatoxin Chemotactic Receptor 1 (CD88 or C5AR1) - Product Development Milestones
Featured News & Press Releases
Jul 06, 2021: Inte Pharma to stop development of avdoralimab for Covid-19
Jul 06, 2021: ChemoCentryx announces filing of amendment to NDA submission and extension of the PDUFA review period for Avacopan in the treatment of ANCA-Associated Vasculitis
Jun 08, 2021: ChemoCentryx announces abstract on Avacopan in ANCA-Associated Vasculitis selected as one of the ten best abstracts at the ERA-EDTA Congress
May 06, 2021: ChemoCentryx announces results of FDA Advisory Committee Meeting on Avacopan in ANCA-associated vasculitis
Mar 02, 2021: Kissei seeks approval for C5aR inhibitor Avacopan in Japan
Feb 17, 2021: ChemoCentryx announces publication in The New England Jourl of Medicine of results of the pivotal phase III ADVOCATE trial of Avacopan for the treatment of ANCA-associated vasculitis
Feb 10, 2021: I-Mab announces Chi NMPA clearance for phase 1 study of TJ210/MOR210 in patients with advanced solid tumors
Jan 25, 2021: I-Mab and MorphoSys announce first patient dosed in U.S. phase 1 study of TJ210/MOR210 in patients with advanced cancer
Dec 21, 2020: VFMCRP and ChemoCentryx provide topline results from ACCOLADE trial of Avacopan in C3 glomerulopathy including improved Estimated Glomerular Filtration Rate (eGFR)
Dec 21, 2020: ChemoCentryx and VFMCRP provide topline results from ACCOLADE trial of Avacopan in C3 Glomerulopathy including improved estimated Glomerular Filtration Rate (eGFR)
Nov 11, 2020: I-Mab announces preclinical data on differentiated Anti-C5aR Antibody TJ210/MOR210 at SITC 2020
Nov 06, 2020: ChemoCentryx announces plery session at ACR Convergence 2020 to highlight findings of ADVOCATE phase III trial in ANCA-associated vasculitis
Nov 03, 2020: VFMCRP and ChemoCentryx announce European Medicines Agency has accepted to review the Marketing Authorization Application for avacopan
Oct 28, 2020: ChemoCentryx announces positive topline results of phase II AURORA clinical trial of Avacopan in the treatment of hidradenitis suppurativa (HS)
Oct 27, 2020: I-Mab to present preclinical data of TJ210 at the 2020 Society for Immunotherapy of Cancer (SITC) Annual Meeting
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures

List of Figures
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Top 10 Indications, 2021
Number of Products by Mechanism of Actions, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Routes of Administration, 2021
Number of Products by Stage and Routes of Administration, 2021
Number of Products by Molecule Types, 2021
Number of Products by Stage and Molecule Types, 2021

List of Tables

List of Tables
Number of Products under Development by Stage of Development, 2021
Number of Products under Development by Therapy Areas, 2021
Number of Products under Development by Indications, 2021
Number of Products under Development by Indications, 2021 (Contd..1)
Number of Products under Development by Companies, 2021
Products under Development by Companies, 2021
Products under Development by Companies, 2021 (Contd..1)
Products under Development by Companies, 2021 (Contd..2)
Number of Products under Investigation by Universities/Institutes, 2021
Products under Investigation by Universities/Institutes, 2021
Number of Products by Stage and Mechanism of Actions, 2021
Number of Products by Stage and Route of Administration, 2021
Number of Products by Stage and Molecule Type, 2021
Pipeline by Alsonex Pty Ltd, 2021
Pipeline by ChemoCentryx Inc, 2021
Pipeline by Dompe Farmaceutici SpA, 2021
Pipeline by Innate Pharma SA, 2021
Pipeline by MorphoSys AG, 2021
Pipeline by Prommune Inc, 2021
Pipeline by Teva Pharmaceutical Industries Ltd, 2021
Pipeline by Visterra Inc, 2021
Dormant Products, 2021
Dormant Products, 2021 (Contd..1)
Discontinued Products, 2021